Targeting Of Sall4 For The Treatment And Diagnosis Of Proliferative Disorders Associated With Myelodysplastic Syndrome (mds)

  • Published: Dec 11, 2008
  • Earliest Priority: Jun 01 2007
  • Family: 8
  • Cited Works: 1
  • Cited by: 2
  • Cites: 0
  • Additional Info: Full text Published

The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are disclosed which demonstrate that constitutive expression of SALL4 increases leukemogenic potential in cells of model animal systems. Moreover, constitutive expression of select isoforms (e.g., SALL4B) in transgenic mice demonstrate that these animals develop myelodysplastic syndrome (MDS)-like signs and symptoms, including subsequent acute myeloid leukemia (AML), which is transplantable. The disclosure also provides methods for identifying and purifying embryonic stem cells, adult stem cells, cancer stem cells, including leukemia stem cells, methods for identifying substances which bind to and/or modulate SALL4, methods for diagnosing MDS in a subject, and methods of treating a subject presenting MDS, AML and other forms of leukemia.

CPC Classifications

Download Citation

Sign in to the Lens